SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| SCYNEXIS (NASDAQ: SCYX) | Delayed: 3.84 -0.1 (2.54%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.94 | 52 Week High | $7.29 | |||
| Open | $3.99 | 52 Week Low | $1.74 | |||
| Day High | $4.00 | P/E | N/A | |||
| Day Low | $3.84 | EPS | $0.00 | |||
| Volume | 22,421 | |||||
